Natera Inc (NASDAQ:NTRA) – Equities researchers at Piper Jaffray Companies issued their FY2021 EPS estimates for Natera in a report issued on Tuesday, October 22nd. Piper Jaffray Companies analyst W. Quirk expects that the medical research company will post earnings of ($1.22) per share for the year. Piper Jaffray Companies currently has a “Buy” rating and a $45.00 price objective on the stock.
Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09. Natera had a negative net margin of 46.78% and a negative return on equity of 273.92%. The firm had revenue of $74.36 million for the quarter, compared to analysts’ expectations of $66.77 million. During the same quarter in the previous year, the company earned ($0.62) earnings per share. The company’s revenue for the quarter was up 17.9% compared to the same quarter last year.
Shares of NASDAQ NTRA traded down $0.21 during midday trading on Thursday, hitting $37.10. 9,990 shares of the company traded hands, compared to its average volume of 851,933. Natera has a 12-month low of $11.08 and a 12-month high of $40.92. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.42 and a current ratio of 2.54. The stock has a 50-day moving average price of $34.47 and a 200 day moving average price of $27.22. The firm has a market cap of $2.63 billion, a P/E ratio of -17.33 and a beta of 1.42.
In other news, COO Robert Alan Schueren sold 12,545 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $33.19, for a total value of $416,368.55. Following the transaction, the chief operating officer now owns 25,000 shares in the company, valued at $829,750. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CTO Jonathan Sheena sold 1,033 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $29.50, for a total transaction of $30,473.50. Following the completion of the transaction, the chief technology officer now owns 241,937 shares in the company, valued at approximately $7,137,141.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 454,648 shares of company stock worth $14,516,636. Corporate insiders own 9.29% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of NTRA. Orbimed Advisors LLC lifted its stake in shares of Natera by 199.2% in the second quarter. Orbimed Advisors LLC now owns 3,224,328 shares of the medical research company’s stock worth $88,927,000 after buying an additional 2,146,742 shares in the last quarter. BlackRock Inc. lifted its position in Natera by 74.4% during the second quarter. BlackRock Inc. now owns 4,842,318 shares of the medical research company’s stock valued at $133,552,000 after purchasing an additional 2,065,977 shares during the period. Invesco Ltd. lifted its position in Natera by 4,307.7% during the second quarter. Invesco Ltd. now owns 2,041,857 shares of the medical research company’s stock valued at $56,314,000 after purchasing an additional 1,995,532 shares during the period. Wells Fargo & Company MN lifted its position in Natera by 1,149.5% during the second quarter. Wells Fargo & Company MN now owns 1,199,174 shares of the medical research company’s stock valued at $33,074,000 after purchasing an additional 1,103,205 shares during the period. Finally, Nuveen Asset Management LLC bought a new position in Natera during the second quarter valued at approximately $24,302,000. Hedge funds and other institutional investors own 94.95% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Investing in Growth Stocks
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.